AZN

AstraZeneca PLC (AZN)

⚠️ No article content returned.

..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 26% Potential Upside and Strong Buy Ratings

AstraZeneca PLC (NYSE: AZN), a stalwart in the healthcare sector, is commanding investor attention with its robust growth prospects and strategic positioning in the global pharmaceutical..

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in..

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial...

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer...

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 26.64% Potential Upside

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, has long garnered attention for its innovation and robust product pipeline. As a leading entity in the..

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio...

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 28.83% Potential Upside in the Healthcare Sector

AstraZeneca PLC (AZN), a prominent player in the healthcare sector, is capturing investor attention with a tantalizing potential upside of 28.83%. With its robust market capitalization..

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 14.93% Potential Upside for Investors

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, continues to capture investor interest with its robust financial performance and strategic initiatives in the biopharmaceutical domain...

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 19% Upside and Robust Revenue Growth

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to draw attention from investors with its impressive market cap of $292.2 billion and a promising..

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer...

AstraZeneca PLC (AZN) Stock Analysis: Robust Growth and Analyst Confidence Propel a 28% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a stalwart in the healthcare sector, is drawing significant investor interest with its impressive market cap of $271.29 billion and a promising..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 25.59% Potential Upside with Strong Buy Ratings

AstraZeneca PLC (AZN), a titan in the healthcare sector, has garnered significant attention from investors, offering a potential upside of 25.59% as per recent analyst evaluations...

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer...

AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential

AstraZeneca PLC (AZN) presents a compelling case for investors seeking opportunities within the healthcare sector. With its headquarters in Cambridge, United Kingdom, this biopharmaceutical titan boasts..

AstraZeneca PLC (AZN) Stock Analysis: Evaluating a Promising 20.91% Upside Potential

AstraZeneca PLC (AZN), a titan in the healthcare sector, holds a prominent position in the drug manufacturing industry. With a staggering market capitalization of $287.95 billion,..

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial..

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and a 20% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a prominent player in the healthcare sector, stands as a titan among global drug manufacturers. With a market capitalization of $290.06 billion,..

Search

Funds

AZN

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal...

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial...

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer...

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio...

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer...

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer...

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival...

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options...
Search

Funds

AZN

FTSE 100

Funds